About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker SNY · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine Wit…
NCT07890454 · Immunization, Healthy Volunteers
IIV-HD (standalone), NVXC19 (EU licensed, standalone)
SNY
Sanofi
Phase 3Recruiting
was not yet recruiting
6,000Dec 28, 2027Registry ↗
Nov 13, 2026Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Table…
NCT07726914 · Chronic Graft Versus Host Disease
Belumosudil, Belumosudil
SNY
Sanofi
Phase 1Not yet recruiting58Jan 26, 2027Registry ↗
Nov 13, 2026Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antig…
NCT07516418 · Respiratory Syncytial Virus (RSV), Influenza A(H5N1)
H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2
SNY
Sanofi
Phase 1Active, not recruiting
was recruiting
360Apr 4, 2027Registry ↗
Nov 13, 2026A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to…
NCT07088068 · Type 1 Diabetes Mellitus
Teplizumab, Placebo
SNY
Sanofi
Phase 3Recruiting723Jun 6, 2028Registry ↗
Nov 13, 2026A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Pati…
NCT04848779 · Glycogen Storage Disease Type II
Alglucosidase alfa GZ419829
SNY
Sanofi
—Completed
was active, not recruiting
9Oct 27, 2026Registry ↗
Nov 12, 2026A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multipl…
NCT07930624 · Multiple Sclerosis
Frexalimab, Frexalimab
SNY
Sanofi
Phase 3Not yet recruiting2,500May 16, 2031Registry ↗
Nov 12, 2026Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased…
NCT07861542 · COVID-19
Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vacci…
SNY
Sanofi
Phase 4Active, not recruiting
was recruiting
669Nov 26, 2026Registry ↗
Nov 12, 2026A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea
NCT07200206 · Respiratory Syncytial Virus
Nirsevimab
SNY
Sanofi
—Recruiting3,000Sep 26, 2029Registry ↗
Nov 12, 2026A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in C…
NCT07156175 · Microscopic Colitis
SAR444336, Placebo
SNY
Sanofi
Phase 2Active, not recruiting
was recruiting
60Apr 8, 2027Registry ↗
Nov 12, 2026Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytope…
NCT07007962 · Immune Thrombocytopenia
rilzabrutinib
SNY
Sanofi
Phase 3Recruiting60Nov 5, 2027Registry ↗
Nov 12, 2026A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Particip…
NCT06500702 · Focal Segmental Glomerulosclerosis, Glomerulonephritis Mini…
frexalimab, brivekimig
SNY
Sanofi
Phase 2Recruiting84Dec 23, 2026Registry ↗
Nov 12, 2026Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan
NCT06052800 · Fabry Disease
SNY
Sanofi
—Completed
was active, not recruiting
78Oct 7, 2026Registry ↗
Nov 10, 2026The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Year…
NCT07927140 · Gaucher's Disease Type III
Venglustat, Imiglucerase
SNY
Sanofi
Phase 3Not yet recruiting18Jan 14, 2030Registry ↗
Nov 10, 2026Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan
NCT07216079 · Immune Thrombocytopenia
rilzabrutinib
SNY
Sanofi
Phase 3Active, not recruiting3Nov 25, 2026Registry ↗
Nov 10, 2026A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic…
NCT07135973 · Chronic Graft Versus Host Disease
Belumosudil
SNY
Sanofi
Phase 4Not yet recruiting26Aug 30, 2027Registry ↗
Nov 9, 2026A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Seve…
NCT07812116 · Hidradenitis
Duvakitug, Placebo
SNY
Sanofi
Phase 2Recruiting
was not yet recruiting
156Jun 16, 2028Registry ↗
Nov 9, 2026Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access…
NCT07457580 · Type 1 Diabetes
Teplizumab
SNY
Sanofi
—Recruiting60Nov 30, 2026Registry ↗
Nov 9, 2026Long-Term Outcomes of Teplizumab in Routine Clinical Care
NCT07360080 · Type 1 Diabetes
Teplizumab
SNY
Sanofi
—Recruiting1,000Oct 29, 2035Registry ↗
Nov 9, 2026Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
NCT06941870 · Factor VIII Deficiency
Efanesoctocog alfa
SNY
Sanofi
Phase 4Recruiting35Oct 25, 2027Registry ↗
Nov 9, 2026Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes
NCT06791291 · Type 1 Diabetes Mellitus
Teplizumab
SNY
Sanofi
Phase 2Active, not recruiting
was recruiting
5Mar 6, 2028Registry ↗
Nov 9, 2026Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressi…
NCT06141486 · Multiple Sclerosis
Frexalimab, Placebo
SNY
Sanofi
Phase 3Active, not recruiting943Mar 24, 2028Registry ↗
Nov 6, 2026An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P…
NCT07923383 · Ulcerative Colitis, Crohn's Disease
Duvakitug
SNY
Sanofi
Phase 1Not yet recruiting25Aug 8, 2028Registry ↗
Nov 6, 2026Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID…
NCT07923305 · Immunodeficiency Common Variable
rilzabrutinib, placebo
SNY
Sanofi
Phase 2/3Not yet recruiting96May 10, 2035Registry ↗
Nov 6, 2026A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy…
NCT07771439 · Chronic Graft Versus Host Disease
Belumosudil, Best available therapy (BAT)
SNY
Sanofi
Phase 3Recruiting
was not yet recruiting
356Sep 14, 2029Registry ↗
Nov 6, 2026A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheim…
NCT07688213 · Dementia, Alzheimer's Type, Alzheimer's Disease
SAR448851, Placebo
SNY
Sanofi
Phase 2Recruiting160Jul 31, 2029Registry ↗
Nov 5, 2026Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (A…
NCT07919899 · Dermatitis Atopic
Dupilumab coformulated with berahyaluronidase alfa, Dupilum…
SNY
Sanofi
Phase 3Not yet recruiting150May 2, 2028Registry ↗
Nov 5, 2026A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clin…
NCT07556159 · Asthma
Procedure: Investigational Procedures, Procedure: Investiga…
SNY
Sanofi
—Recruiting2,500Apr 4, 2029Registry ↗
Nov 5, 2026A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population
NCT07103148 · Yellow Fever Immunization
Yellow fever vaccine (live), Yellow fever vaccine (live)
SNY
Sanofi
Phase 3Active, not recruiting
was recruiting
2,440Nov 28, 2026Registry ↗
Nov 3, 2026Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06058156 · Atopic Dermatitis
SAR444656 (KT-474), Placebo
SNY
Sanofi
Phase 2Terminated70Oct 23, 2025Registry ↗
Nov 2, 2026This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic De…
NCT07290803 · Atopic Dermatitis
SNY
Sanofi
—Recruiting1,000Jan 30, 2034Registry ↗
Nov 2, 2026A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative…
NCT06975722 · Ulcerative Colitis
SAR442970, Placebo
SNY
Sanofi
Phase 2Active, not recruiting105Dec 17, 2026Registry ↗
Nov 2, 2026A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
NCT06958536 · Crohn's Disease
brivekimig, Placebo
SNY
Sanofi
Phase 2Recruiting99Dec 17, 2026Registry ↗
Nov 2, 2026Phase 1 Study of Chlamydia Trachomatis mRNA Vaccine in Adults.
NCT06891417 · Chlamydia Trachomatis Immunization
Chlamydia mRNA Vaccine, Placebo
SNY
Sanofi
Phase 1Recruiting80Nov 3, 2027Registry ↗
Nov 2, 2026Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adoles…
NCT06111586 · Type 1 Diabetes Mellitus
Frexalimab, Placebo
SNY
Sanofi
Phase 2Active, not recruiting197Apr 28, 2027Registry ↗
Oct 30, 2026A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outc…
NCT07906132 · Atherosclerotic Cardiovascular Disease
SNY
Sanofi
—Completed93,000Jul 11, 2026Registry ↗
Oct 29, 2026A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Ato…
NCT07905547 · Atopic Dermatitis
Dupilumab
SNY
Sanofi
Phase 4Not yet recruiting56Feb 7, 2027Registry ↗
Oct 29, 2026A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outc…
NCT07905534 · Atherosclerotic Cardiovascular Disease
SNY
Sanofi
—Active, not recruiting18,000Aug 21, 2026Registry ↗
Oct 29, 2026A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outc…
NCT07905508 · Atherosclerotic Cardiovascular Disease
SNY
Sanofi
—Completed180,000Jun 30, 2026Registry ↗
Oct 29, 2026Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alf…
NCT07646548 · Healthy Volunteers
Dupilumab coformulated with berahyaluronidase alfa, Dupilum…
SNY
Sanofi
Phase 1Completed
was active, not recruiting
40Sep 30, 2026Registry ↗
Oct 28, 2026A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves'…
NCT06984627 · Graves' Disease
Rilzabrutinib dose 1, Rilzabrutinib dose 2
SNY
Sanofi
Phase 2Recruiting30Feb 11, 2027Registry ↗
Oct 28, 2026Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinu…
NCT06914908 · Chronic Rhinosinusitis With Nasal Polyps
Lunsekimig, Mometasone furoate nasal spray (MFNS)
SNY
Sanofi
Phase 2Active, not recruiting71Feb 22, 2029Registry ↗
Oct 28, 2026A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic…
NCT06082037 · Lung Transplant Rejection
Belumosudil, Azithromycin
SNY
Sanofi
Phase 3Recruiting180Jan 29, 2029Registry ↗
Oct 28, 2026Pompe Disease Registry Protocol
NCT00231400 · Glycogen Storage Disease Type II, Pompe Disease
SNY
Genzyme, a Sanofi Company
—Recruiting2,000Jan 31, 2034Registry ↗
Oct 27, 2026A Study to Describe Multiple Sclerosis Patients Treated With Tolebrutinib as Per Label in a Real-wo…
NCT07898371 · Multiple Sclerosis
Tolebrutinib
SNY
Sanofi
—Recruiting3,000Sep 21, 2031Registry ↗
Oct 27, 2026SAR447971 First-in-human Study
NCT07629336 · Hidradenitis, Healthy Volunteers
SAR447971, Placebo
SNY
Sanofi
Phase 1Recruiting122Apr 17, 2028Registry ↗
Oct 27, 2026A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1…
NCT07285460 · Hemophilia
Fitusiran, Clotting factor concentrates (CFC) or bypassing…
SNY
Sanofi
Phase 3Recruiting85Aug 4, 2029Registry ↗
Oct 27, 2026Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099 · Polyneuropathy, Inflammatory Demyelinating, Chronic
Riliprubart Prefilled Pen (PFP)
SNY
Sanofi
Phase 3Enrolling by invitation300Oct 3, 2029Registry ↗
Oct 26, 2026A Study to Describe Patient REal-world FitusiRan ExpeRience
NCT07895381 · Hemophilia A or B
SNY
Sanofi
—Not yet recruiting100Mar 2, 2029Registry ↗
Oct 26, 2026A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexametha…
NCT06356571 · Plasma Cell Myeloma Refractory
Isatuximab SC-OBDS, Montelukast
SNY
Sanofi
Phase 2Active, not recruiting64Apr 1, 2027Registry ↗
Oct 23, 2026Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants W…
NCT07853131 · Renal Impairment, Healthy Volunteers
rilzabrutinib
SNY
Sanofi
Phase 1Recruiting16Apr 21, 2027Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 10:34 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances